NCT06752720 (RAINBOW-2a) is a Phase 2 clinical trial of Stem cell Transplantation in Stroke, sponsored by Hokkaido University Hospital.

Who is sponsoring NCT06752720?

NCT06752720 is sponsored by Hokkaido University Hospital.

What drugs are being tested in NCT06752720?

Interventions in NCT06752720: Stem cell Transplantation.

What condition does NCT06752720 study?

NCT06752720 studies Stroke, Stroke, Ischemic, Stroke; Sequelae.

Is NCT06752720 still recruiting?

NCT06752720 is currently recruiting now. Last updated 24 January 2025.

Last reviewed 2025-01-24 · How we verify

NCT06752720: RAINBOW-2a

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intracerebral Autologous Stem Cell Therapy for Chronic Stroke Patients

Recruiting now Phase 2 Last updated 24 January 2025

What this trial tests

Phase 2 trial testing Stem cell Transplantation in Stroke in 8 participants. Currently enrolling.

Timeline

1 December 2024

Primary endpoint
31 December 2025

30 November 2027

Quick facts

Lead sponsor	Hokkaido University Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	1 December 2024
Primary completion	31 December 2025
Estimated completion	30 November 2027
Sites	1 location across Japan

Drugs / interventions tested

Stem cell Transplantation — full drug profile →

Conditions studied

Stroke — all drugs for Stroke →
Stroke, Ischemic — all drugs for Stroke, Ischemic →
Stroke; Sequelae — all drugs for Stroke; Sequelae →

Sponsor

Hokkaido University Hospital

Who can join

Adults 20 to 70, any sex, with Stroke or Stroke, Ischemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to evaluate if autologous mesenchymal stem cell (HUNS001-01) transplantation therapy can provide neurological recovery in patients with chronic stage of stroke resulting in moderate to severe neurological sequelae. The main questions it aims to answer are: Can HUNS001-01 intracerebral transplantation demonstrate improvement in the mRS of disability for 1 year after intervention? Can HUNS001-01 intracerebral transplantation can be performed without any adverse events for 1 year after intervention? Participants will receive the below interventions. * Screening for the eligibility to enroll the clinical trial (interview, blood test, imaging) * Harvest of platelet concentrates (PC) * Harvest of bone marrows (BM) * Receive intracerebral transplantation surgery of HUNS001-01 * Post-operative rehabilitation * Follow-up studies (until 1 year or termination of the trial)

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.
Mazurek CY, Kaniuk JK, Ahuja CS. · · 2026 · PMID 41809632 · DOI 10.3389/fnmol.2026.1742864
Cell therapy for stroke and spinal cord injury in clinical trials.
Fan Y, Wong ST, Goh ELK, Chan JKY. · · 2026 · PMID 41641797 · DOI 10.1093/stcltm/szaf082

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

NCT06615973 — Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke · recruiting
NCT07494890 — Measurement Properties of Mechanical Cost of Walking for Individuals With Walking Impairment · NA · recruiting
NCT07356011 — Exoskeleton for Balance · NA · recruiting
NCT07523503 — Unilateral Versus Bilateral Task-specific Training on Motor Impairment, Upper Extremity Function, and Hand Dexterity in · NA · recruiting
NCT06704074 — Virtual Reality Task Oriented Training on Upper Limb Function in Stroke Patients · NA · recruiting

Other Hokkaido University Hospital trials

Trials by the same sponsor.

NCT05252429 — Docetaxel/Pembrolizumab in Head and Neck Squamous Cell Carcinoma · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06752720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hokkaido University Hospital
Last refreshed: 24 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06752720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing